Skip to main content

DC Funds, LP

13F filer · CIK 0001869028
Reported Aug 14, 2026
13F portfolio value$1.25MU.S. long equity reported on 13F
Positions3Not reported new · Not reported closed
Net flow last quarterNot reportedBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 20263 positions
TCRXTScan Therapeutics, Inc.$617K49.27%2.63%Not reportedQ3 2021
BRNSBarinthus Biotherapeutics plc.$424K33.82%1.57%Not reportedQ2 2021
HOWLWerewolf Therapeutics, Inc.$212K16.92%1.21%Not reportedQ2 2021
Q1 2026Reported May 14, 20263 positions
TCRXTScan Therapeutics, Inc.$630K42.40%2.63%Not reportedQ3 2021
HOWLWerewolf Therapeutics, Inc.$490K33.01%1.21%Not reportedQ2 2021
BRNSBarinthus Biotherapeutics plc.$365K24.59%1.57%Not reportedQ2 2021
Q4 2025Reported Feb 13, 20263 positions
TCRXTScan Therapeutics, Inc.$630K43.36%2.63%Not reportedQ3 2021
BRNSBarinthus Biotherapeutics plc.$450K30.95%1.57%Not reportedQ2 2021
HOWLWerewolf Therapeutics, Inc.$373K25.69%1.21%Not reportedQ2 2021
Q3 2025Reported Nov 10, 20253 positions
HOWLWerewolf Therapeutics, Inc.$1.16M37.32%1.25%Not reportedQ2 2021
TCRXTScan Therapeutics, Inc.$1.15M36.87%2.63%Not reportedQ3 2021
BRNSBarinthus Biotherapeutics plc.$803K25.81%1.57%Not reportedQ2 2021
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.